Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Entyvio SC Form Now under EMA Review: Takeda
Takeda Pharmaceutical said on April 1 that the European Medicines Agency (EMA) has accepted a subcutaneous formulation of Entyvio (vedolizumab) for review as a maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD).…
To read the full story
Related Article
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
February 18, 2020
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda
July 20, 2018
BUSINESS
- Ajinomoto Builds Presence in ADC CDMO Business with Proprietary Technology
January 27, 2026
- Leqembi Iqlik Now under FDA Review for Initiation Phase
January 26, 2026
- Regeneron Japan Launches Scholarship for STEM-Oriented High School Students
January 26, 2026
- JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO
January 26, 2026
- Solasia to Grant MAAB Rights to Antiemetic Drug in China
January 26, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…